Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

BACKGROUND: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypothesized that activation of phosphorylated EGFR could be...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wang, Fen, Wang, Shuhang, Wang, Zhijie, Duan, Jianchun, An, Tongtong, Zhao, Jun, Bai, Hua, Wang, Jie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2012
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548765/
https://ncbi.nlm.nih.gov/pubmed/22901364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-31-65
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak